The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.
The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
In Science this week: environmental DNA can help in studies of marine animals, and more.
BioClin is developing a monoclonal antibody-based treatment for relapsed/refractory metastatic urothelial carcinoma with FGFR3 molecular alterations.
The company presented three posters at AACR, two of which demonstrated insights from its circulating DNA monitoring in colorectal and bladder cancers.
Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
Using an integrated omics approach, researchers identified non-muscle invasive bladder cancer subtypes, along with pathways that are frequently altered in the disease.
The company believes the approach could allow researchers to profile tumor signaling pathways via blood or urine samples, similar to how ctDNA analysis is used.
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.